| Publications
Original Articles
AW
Harris, A Douds, EV Meurisse, S Chambers, SR Gould.
High seroprevalence of Helicobacter pylori in residents of a hospital
for people with severe learning difficulties.
Eur J Gastroenterol Hepatol 1995; 7: 21-23
AW
Harris, PA Gummett, RPH Logan, HA Ashworth, JJ Misiewicz, JH
Baron.
Eradication of Helicobacter pylori with lansoprazole and clarithromycin.
Aliment Pharmacol Ther 1995; 9: 201-204
AW
Harris, MM Walker, A Smolka, JM Waller, JH Baron, JJ Misiewicz.
Prevalence of parietal cells in the duodenal bulb & relationship
to H pylori infection
Journal of Clinical Pathology 1996; 49: 309-312
AW
Harris, PA Gummett, JJ Misiewicz, JH Baron.
Eradication of Helicobacter pylori lowers acid output in patients
with duodenal ulcer.
Gut 1996; 38: 663-667
AW
Harris, MM Walker, JM Waller, JH Baron, JJ Misiewicz.
The relationship between duodenal gastric metaplasia, acid output
and H pylori
Gut 1996; 39: 513-520
AW
Harris, DI Pryce, SM Gabe, et al.
Lansoprazole, clarithromycin & metronidazole for one week
cures H pylori infection.
Aliment Pharmacol Ther 1996; 10 (6):1005-1008
AW
Harris, PA Gummett, P Phull, MR Jacyna, JJ Misiewicz, JH Baron.
Recurrence of duodenal ulcer after H pylori eradication is related
to high acid output
Aliment Pharmacol Ther 1997; 11: 331-334.
JJ Misiewicz, AW
Harris, KD Bardham, et al.
One week triple therapy for Helicobacter pylori: a multi-centre
comparative study.
Gut 1997; 41: 735-739
AW
Harris, JJ Misiewicz, KD Bardham et al.
Incidence of duodenal ulcer healing after one week of PPI triple
therapy for eradication of Helicobacter pylori.
Aliment Pharmacol Ther 1998; 12 (8): 741-745
Moayyedi P, on behalf of the Dyspepsia Review Group (includes
AW Harris).
Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia.
BMJ 2000; 321: 659-664.
Fox MR, Harris AW.
An assessment of open access referral for PEG in a district general
hospital.
Eur J Gastroenterol Hepatol 2002; 14 (11): 1245-49
Moayyedi P, Soo S, Deeks J, Forman D, Harris AW,
Innes M, Delaney B.
Systematic review: antacids H2-receptor antagonists, prokinetics,
bismuth and sucralfate therapy for non-ulcer dyspepsia.
Aliment Pharmacol Ther 2003: 17: 1215-1227
Hayee BH, Harris AW
Methotrexate for Crohn’s disease: experience in a district
general hospital
Eur J Gastroenterol Hepatol 2005; 17 (9): 893-898
KM Taylor, K Arajs, T Rouse, AW Harris
Prospective audit of colonoscopy quality in Kent and Medway, UK.
Endoscopy 2008; 40:1-4
Reviews, Leading Articles and Letters in Learned Journals
AW
Harris, JJ Misiewicz.
Hitting H. pylori for four
Lancet 1995; 345: 806-807.
AW Harris
Helicobacter pylori testing at home
Eur J Gastroenterol Hepatol 1995; 7: 595-596
AW
Harris, JJ Misiewicz
Treating Helicobacter pylori - the best is yet to come?
Gut 1996; 39 (6): 781-783
AW Harris
Helicobacter pylori and urea breath testing. Can the breath test
result predict the outcome of treatment?
Italian Journal of Gastroenterology and Hepatology 1998;30: 151-2
AW Harris
Current regimens for treatment of Helicobacter pylori
In: Farthing MJG and Patchett SE, eds. British Medical Bulletin:
Helicobacter infection
1998; 54 (1): 195-205
AW Harris
Understanding Inflammatory Bowel Disease.
In: CR-ROM “Inflammatory Bowel Diseases” Schreiber
S et al. Walter de Gruyter GmbH, Berlin, 1998
AW Harris
Drugs, Diseases and Disorders: Pentasa in ulcerative colitis
NHS Doctor and Commissioning GP Summer 1998: 57-8
AW Harris
Inflammatory bowel disease: safety of current therapies
Hospital Update Supplement August 1998: 9-10
AW Harris
Treatment of H pylori
World Journal of Gastroenterology 2001; 7 (3): 303-307
Adam Harris, JJ Misiewicz
Management of Helicobacter pylori infection
British Medical Journal 2001; 323: 1047-50
BH Hayee, AW Harris
6-mercaptopurine and mesalasine for prevention of relapse after
conservative surgery for Crohn’s disease.
Gastroenterology 2005; 128(1): 249
G Sisson, AW Harris
Certolizumab Pegol for treatment of Crohn’s disease.
Gastroenterology 2006; 130(1): 285-286
K Taylor, AW Harris
Ulcerative Colitis: an overview
Chemist and Druggist 5 May 2007: 34-38
AW Harris
Gastroenterology in 2050
Hospital Doctor June 2007
KM Taylor, AW Harris
Extent of colonoscopy.
Gastroenterology 2007;133:1391-2
Books
AW
Harris, JJ Misiewicz.
Clinician's Manual on Helicobacter pylori
Science Press Limited, London, 1995 (Second edition 1997).
AW
Harris, JJ Misiewicz.
Helicobacter pylori
Blackwell Scientific Publications Limited, Oxford, 1996.
AW
Harris, JJ Misiewicz
Lecture notes on Helicobacter pylori
Rapid Science Press Limited, London, 1996.
AW Harris
CD-ROM: Peptic ulcer disease
RSM Press, London, 1998
Eds: Baron JH, Logan R, Harris
AW, Misiewicz JJ.
ABC of Upper Gastrointestinal Tract
BMJ, London, 2002 (ISBN 0-7279-1266-6)
AW Harris
Handbook of Gastrointestinal Emergencies
Science Press Limited, London 2002 (ISBN 1-85873-394-4)
Recent Abstracts at
British Society of Gastroenterology Meetings
Maiden LP, Lawson GJ, Harris AW.
Development of human anti-murine
antibodies in patients following treatment with infliximab.
Gut
2003; 52 (Suppl 1): A62
Maiden LP, Harris AW.
Parenteral methotrexate in refractory Crohn’s
disease: experience in a district general hospital.
Gut 2003; 53
(Suppl 1): A63
Hayee BH, Barnden M, Harris AW.
Waiting list validation for screening
and surveillance colonoscopy.
Gut 2005; 54 (Suppl 11): A74.
Hayee BH, Basavarajaiah, Harris AW.
Guided primary care management
of inflammatory bowel disease.
Gut 2005; 54 (Suppl 11): A107.
AW Harris, K Arajs, T Rouse.
Prospective audit of colonoscopy quality in Kent & Medway
Gut 2006;55 (Suppl 11): A8
G Sisson, AW Harris.
Is conscious sedation practiced safely in patients undergoing colonoscopy
Gut 2006; 55 (Suppl 11): A 94
S McLaughlin, AW Harris
Audit of 30 day mortality following PEG insertion in a District General Hospital compared with NCEPOD results.
Gut 2007; 56 (suppl 1):A95
T Demetriou, C Gawad, C Kok, AW Harris.
Two year prospective audit of use of liquid diets as “bridge” therapy for active Crohn’s disease.
Gut 2008;57 (Suppl 1): A18
KM Taylor, AW Harris.
Infliximab as a treatment for ulcerative colitis: 3 years experience in a district general hospital.
Gut 2008;57 (Suppl 1): A149
|